According to a new report Global Fusion Biopsy Market, published by KBV research, The Global Fusion Biopsy Market size is expected to reach $912.5 Million by 2026, rising at a market growth of 11.5% CAGR during the forecast period.
By Route, the transrectal segment has registered the largest market share in the year 2019 because from the past few decades, it is acting as the gold standard to carry out prostate biopsy worldwide. Moreover, many fusion biopsies are that are commercially available are limited to the transrectal approach, therefore, it is contributing to the largest market share for the transrectal segment. Transperineal fusion biopsy is an evolving trend and is anticipated to show the fastest growth in the foreseeable period of time. It has a lower risk of infection and minimal rectal bleeding as compared to the traditional approach is likely to have a positive driver towards the segment growth.
By end use, the hospital segment registered the largest market share in the year 2019. The factors like the large patient pool, the presence of advanced MRI equipment, high financial capabilities, and the availability of skilled professionals are anticipated to have a positive contribution towards its largest market share. Diagnostics centers are anticipated to grow at a substantial rate in the coming years. It reduces wait times, developing reimbursement paradigm, and cost efficiency is some of the factors that are likely to drive the growth of the fusion biopsy market.
North America holds the largest revenue share in the fusion biopsy market in the year 2019 and is likely to show its dominance over the foreseeable period of time. The presence of an efficient compensation framework, increasing incidence of prostate cancer, and a rise in R&D outflow related to prostate cancer care and treatment are the factors that have contributed to its largest market share. Asia Pacific is expected to show the fastest growth rate in the forecasted years. The rising awareness among urologists about the functions and features as well as sensitivity and specificity of the targeted MR/Ultrasound biopsy while performing a prostate biopsy is likely to drive the market.
Structural Insights: https://www.kbvresearch.com/fusion-biopsy-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Koninklijke Philips N.V., Hitachi, Ltd., Baxter International, Inc. (MedCom), Esaote SpA, Eigen, KOELIS, Inc., Focal Healthcare, Inc., and UC-Care Medical Systems Ltd.
Global Fusion Biopsy Market Segmentation
By End Use
- Diagnostic centers
- Ambulatory care centers
- Rest of North America
- Rest of Europe
- South Korea
- Rest of Asia Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Koninklijke Philips N.V.
- Hitachi, Ltd.
- Baxter International, Inc. (MedCom)
- Esaote SpA
- KOELIS, Inc.
- Focal Healthcare, Inc.
- UC-Care Medical Systems Ltd.